Patient Management

2074 soru

Soru 1581Soru →

Determine the most appropriate validated risk stratification tool used to guide the immediate care setting disposition (e.g., safe outpatient discharge versus hospital admission) for each clinical scenario. Match each patient presentation to its corresponding disposition tool.

Soldaki öğeye tıklayın, sonra eşleşen sağdaki öğeye tıklayın

Öğeler

A 68-year-old patient evaluated in the emergency department for fever, productive cough, and a new lobar infiltrate on chest radiograph.
A 60-year-old patient evaluated in the emergency department for a single episode of melena, blood urea nitrogen of 28 mg/dL, and stable vital signs.
A 45-year-old patient evaluated in the emergency department for sudden-onset pleuritic chest pain, normal vital signs, and a positive computed tomography pulmonary angiogram.
A 50-year-old patient evaluated in the emergency department for acute, non-radiating chest discomfort, a normal electrocardiogram, and negative initial troponin.

Eşleşmeler

Cevabı ve açıklamayı göster

Cevap

Community-Acquired Pneumonia matches CURB-65; Upper GI Bleeding matches Glasgow-Blatchford Score; Pulmonary Embolism matches PESI; Undifferentiated Chest Pain matches HEART Score.
Each clinical scenario corresponds to a specific acute condition where the immediate care setting disposition (outpatient vs. inpatient vs. ICU) is guided by a validated risk score. The CURB-65 score objectively evaluates community-acquired pneumonia. The Glasgow-Blatchford Score (GBS) evaluates the need for admission in upper gastrointestinal bleeding. The Pulmonary Embolism Severity Index (PESI) determines if outpatient management is safe for acute pulmonary embolism. The HEART score assesses undifferentiated chest pain to safely rule out acute coronary syndrome and avoid unnecessary hospital admissions.

Adım Adım Çözüm

1
Identify the underlying primary acute clinical condition for each patient vignette.
The scenarios describe community-acquired pneumonia, upper gastrointestinal bleeding, acute pulmonary embolism, and undifferentiated chest pain.
Disposition pathways and triage decisions are protocolized based on the specific acute disease process.
2
Determine the objective, disease-specific risk stratification tool intended to evaluate severity for each condition.
Pneumonia uses CURB-65 (or PSI); Upper GI bleed uses Glasgow-Blatchford; PE uses PESI; Chest pain uses HEART.
Safe care setting transitions require moving beyond clinical gestalt to objective mortality and complication risk prediction.
3
Map the specific scoring systems to their respective patient presentations.
Match each tool to its clinical scenario based on its role in guiding the immediate transition from the emergency department to either outpatient care or hospital admission.
This establishes the appropriate disposition pathway directly addressing the patient's immediate triage needs.

Anahtar Kavram

Validated risk stratification tools objectively guide disposition and care setting transitions by predicting short-term adverse outcomes, thereby identifying which patients are safe for outpatient management and which require hospital admission.
Soru 1582Soru →

A 78-year-old man is evaluated for discharge planning on hospital day 12 following admission for a severe acute ischemic stroke. His hospital course was complicated by aspiration pneumonia, which has now fully resolved after a 7-day course of intravenous antibiotics. His medical history includes moderate chronic obstructive pulmonary disease (COPD) and hypertension.

Currently, the patient is hemodynamically stable and his oxygen saturation is 95% on room air. Neurological examination shows dense left-sided hemiparesis and left homonymous hemianopia. He has moderate oropharyngeal dysphagia but is safely tolerating a mechanical soft diet with thickened liquids.

Physical and occupational therapy evaluations indicate that he requires maximal assistance for bed mobility and transfers from bed to chair. He is cognitively intact, highly motivated, and actively participates in his rehabilitation sessions. However, due to dyspnea from his underlying COPD and generalized deconditioning, he experiences severe exhaustion and can only participate in 60 to 90 minutes of combined therapy per day before requiring prolonged rest.

He lives in a single-story home with his 76-year-old wife, who has severe rheumatoid arthritis and is physically unable to assist with his transfers. The patient has standard Medicare coverage and limited out-of-pocket financial resources.

Which of the following is the most appropriate discharge disposition for this patient?

Cevabı ve açıklamayı göster

Cevap: Skilled nursing facility

Cevap

Skilled nursing facility
The correct disposition is a skilled nursing facility (SNF). This patient has ongoing subacute rehabilitation needs following a severe stroke, but he cannot be safely discharged home because he requires maximal assistance for transfers, which his wife cannot provide due to her severe rheumatoid arthritis. Although he is highly motivated, his severe deconditioning and COPD limit his therapy tolerance to 60-90 minutes daily. This strictly disqualifies him from an inpatient rehabilitation facility (IRF), which requires patients to tolerate and benefit from intensive rehabilitation consisting of at least 3 hours of therapy per day (or 15 hours over a 7-day period). An SNF is the appropriate level of care because it can safely manage his transfer needs and provide lower-intensity rehabilitation (typically 1-2 hours per day) covered by Medicare following a qualifying inpatient hospital stay.

Adım Adım Çözüm

1
Assess the patient's medical stability.
The patient is hemodynamically stable, the pneumonia is resolved, and he no longer requires daily acute physician intervention.
Medical stability rules out the need for continued acute inpatient care or a Long-term acute care hospital (LTACH).
2
Evaluate the patient's functional needs and social support.
He requires maximal assistance for transfers, and his wife is physically unable to provide this assistance.
A lack of adequate physical support at home makes discharge to the home setting (even with intermittent home health) unsafe.
3
Determine the patient's rehabilitation tolerance and potential.
He is motivated but can only tolerate 60 to 90 minutes of combined therapy per day due to cardiopulmonary limitations.
Inpatient rehabilitation facilities (IRFs) mandate a tolerance of 3 hours of daily intensive therapy. Since he cannot meet this requirement, a skilled nursing facility (SNF) is the most appropriate setting for his subacute rehabilitation needs.

Anahtar Kavram

Patients who require post-acute rehabilitation and nursing care, but cannot tolerate the intensive 3-hour daily therapy requirement of an Inpatient Rehabilitation Facility (IRF), should be discharged to a Skilled Nursing Facility (SNF).
Soru 1583Soru →

A 4242-year-old female with a history of bipolar disorder is brought to the emergency department by her family due to progressively worsening lethargy, coarse tremors, and severe ataxia over the past three days. She has been stable on lithium carbonate for five years but was recently prescribed lisinopril for hypertension by her primary care physician. Initial laboratory evaluation reveals a serum lithium concentration of 3.8 mEq/L3.8 \text{ mEq/L} and a serum creatinine of 2.4 mg/dL2.4 \text{ mg/dL} (baseline 0.9 mg/dL0.9 \text{ mg/dL}). Arrange the following therapeutic and monitoring actions in the most appropriate chronological sequence for managing this patient's condition.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct clinical sequence is to begin with intravenous fluid resuscitation, proceed to emergent intermittent hemodialysis, monitor lithium levels every 2 to 4 hours to detect tissue rebound, perform a repeat hemodialysis session if rebound reaches toxic levels, and finally transition to daily monitoring once stable.
Severe acute-on-chronic lithium toxicity with acute kidney injury (AKI) requires a specific sequenced treatment and monitoring protocol. Management must begin with aggressive isotonic intravenous fluids to correct volume depletion and maximize glomerular filtration. Because the patient demonstrates severe neurological symptoms and a lithium level >2.5 mEq/L>2.5 \text{ mEq/L} with AKI, emergent intermittent hemodialysis is definitively indicated to rapidly clear the toxin. Crucially, lithium has a large volume of distribution and shifts slowly from the intracellular to the intravascular space. Hemodialysis only clears the intravascular compartment; thus, once dialysis stops, lithium redistributes from tissues back into the blood. Therefore, the treatment evaluation necessitates measuring serum levels every 22 to 44 hours immediately post-dialysis to monitor for this 'rebound' effect. A second hemodialysis session is frequently required to clear this redistributed load. Finally, once levels are consistently <1.0 mEq/L<1.0 \text{ mEq/L} without further rebound, monitoring can be safely de-escalated to a daily frequency.

Adım Adım Çözüm

1
Administer aggressive intravenous isotonic saline.
Corrects hypovolemia and maximizes endogenous renal clearance.
The patient's lithium retention is worsened by ACE inhibitor-induced efferent arteriolar vasodilation and volume depletion. Restoring renal perfusion is the mandatory first step while coordinating advanced therapies.
2
Initiate intermittent hemodialysis.
Rapidly extracts lithium from the intravascular compartment.
Hemodialysis is strictly indicated for lithium toxicity when serum levels exceed 2.5 mEq/L in the setting of acute kidney injury, severe neurological symptoms, or both.
3
Measure serum lithium concentrations every 2 to 4 hours post-dialysis.
Evaluates the expected post-dialysis rebound in serum lithium concentration.
Because lithium slowly moves from the intracellular to the intravascular space, a significant rebound in serum levels predictably occurs 2 to 8 hours after the termination of hemodialysis.
4
Perform a second session of hemodialysis.
Clears the redistributed intravascular lithium burden.
The rebound phenomenon often pushes serum levels back into the toxic range, requiring sequential dialysis runs to achieve definitive clearance.
5
Transition to daily serum lithium monitoring.
Confirms sustained non-toxic levels without extracorporeal assistance.
Once the rebound phase has passed and levels remain consistently sub-therapeutic or normal (<1.0 mEq/L), intensive monitoring can be safely de-escalated.

Anahtar Kavram

Management and post-dialysis rebound monitoring in severe lithium toxicity.
Soru 1584Soru →

A 22-year-old woman is brought to the emergency department by her roommate 2 hours after intentionally ingesting an unknown quantity of acetaminophen. She is currently asymptomatic. Her vital signs are within normal limits, and her physical examination is unremarkable. Intravenous access is established. Arrange the following steps in the most appropriate chronological order for evaluating and monitoring this patient's potential acetaminophen toxicity.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct sequence is to first wait until 4 hours post-ingestion to obtain a serum acetaminophen level, then plot this level on the Rumack-Matthew nomogram, initiate N-acetylcysteine if indicated, and finally monitor serial liver chemistries to determine when to discontinue therapy.
The evaluation and monitoring of acute acetaminophen toxicity follows a strict protocol to maximize diagnostic accuracy and therapeutic efficacy. Because acetaminophen requires time to be fully absorbed and distributed from the gastrointestinal tract, serum levels drawn prior to 4 hours post-ingestion are clinically uninterpretable. Therefore, the first step is to obtain a level exactly at the 4-hour mark. Once this level is obtained, it is plotted on the Rumack-Matthew nomogram, which graphs serum concentration against time since ingestion. If the coordinates fall on or above the standard treatment line, the patient is at significant risk for hepatotoxicity, and N-acetylcysteine (NAC) should be initiated. Since the antidote is nearly 100% effective at preventing liver damage if given within 8 hours of ingestion, waiting for the 4-hour level in an early-presenting patient is both safe and appropriate. Finally, the duration of NAC therapy is guided by ongoing monitoring. The infusion is continued until the patient is asymptomatic, acetaminophen levels are undetectable, liver transaminases are clearly improving, and synthetic liver function (INR) is normal.

Adım Adım Çözüm

1
Obtain a serum acetaminophen level at 4 hours post-ingestion.
An interpretable serum concentration is acquired.
Acetaminophen absorption is not complete before 4 hours; levels drawn earlier cannot accurately predict toxicity.
2
Plot the level on the Rumack-Matthew nomogram.
The patient's risk of developing hepatotoxicity is stratified.
The nomogram provides an evidence-based treatment line to guide clinical decision-making.
3
Initiate N-acetylcysteine (NAC) therapy if indicated by the nomogram.
Antidote therapy is started to replenish glutathione stores.
Starting NAC within 8 hours of ingestion prevents hepatotoxicity in nearly all patients.
4
Monitor serial liver chemistries (AST/ALT) and coagulation studies (INR).
The patient's clinical trajectory and treatment response are assessed.
Resolution of hepatic injury markers dictates when it is safe to discontinue NAC therapy.

Anahtar Kavram

In acute acetaminophen ingestions presenting under 8 hours, clinicians should wait until 4 hours post-ingestion to obtain a serum level, plot it on the Rumack-Matthew nomogram to guide N-acetylcysteine initiation, and monitor serial liver chemistries to determine when to safely discontinue therapy.
Soru 1585Soru →

An 82-year-old woman is evaluated for discharge planning. She was admitted 4 days ago for an acute kidney injury secondary to poor oral intake and dehydration, which has fully resolved with intravenous fluids. During the hospitalization, the medical team notes significant cognitive deficits. A Montreal Cognitive Assessment (MoCA) score is 15/30. Her daughter, who lives in another state and cannot provide direct care, arrives and reports that the patient has recently been getting lost in her own neighborhood, forgetting to pay bills, and leaving the stove burner on unattended. The patient currently lives alone in a single-story house.

Physical and occupational therapy evaluations determine that the patient is independently ambulatory without an assistive device. She is physically capable of transferring, bathing, and dressing herself, although she requires frequent verbal cueing to initiate and complete these tasks. She takes only oral medications for hypertension and hypothyroidism. She does not require any intravenous medications, wound care, or ongoing physical therapy. Both the patient and her daughter agree that the patient can no longer safely live alone and wish to transition her to an appropriate facility.

Which of the following is the most appropriate care setting for this patient's disposition?

Cevabı ve açıklamayı göster

Cevap: Assisted living facility

Cevap

Assisted living facility
The correct answer is an assisted living facility. This patient has moderate dementia with significant safety risks (wandering, leaving the stove on) and impairment in instrumental activities of daily living (IADLs), requiring 24-hour supervision and cueing. However, she is physically independent, requires only oral medications, and has no active need for daily skilled nursing care (e.g., complex wound care, intravenous medications) or skilled therapy (e.g., daily physical therapy). Assisted living facilities provide housing, meals, continuous supervision, and assistance with ADLs and IADLs, which perfectly matches her need for custodial care rather than skilled medical care.

Adım Adım Çözüm

1
Evaluate the patient's physical and medical needs.
The patient is physically independent (ambulates well, physically capable of ADLs) and requires only oral medications. She has no skilled nursing or intensive therapy needs.
Determining the presence or absence of skilled needs is the first step in ruling out high-acuity facilities like a skilled nursing facility or inpatient rehabilitation facility.
2
Evaluate the patient's cognitive status and safety requirements.
The patient has significant cognitive impairment (MoCA 15/30), requires verbal cueing for ADLs, and displays unsafe behaviors at home (wandering, leaving the stove on).
Cognitive deficits often drive disposition decisions when physical needs are low, as these patients require continuous supervision to ensure safety.
3
Match the patient's combined needs to the appropriate post-acute care setting.
An assisted living facility (or memory care unit) provides the necessary 24-hour supervision, safety monitoring, and assistance with IADLs/ADLs without requiring a skilled medical justification.
Appropriate resource utilization ensures patient safety without over-triaging to a medicalized setting or under-triaging to home health, which cannot provide 24/7 supervision.

Anahtar Kavram

Indications for post-acute care settings are based on the combination of skilled medical/therapy needs and the requirement for custodial supervision.
Soru 1586Soru →

A primary care physician is reviewing the electronic health records of four established patients who are scheduled for annual health maintenance visits this morning. Match each patient's specific clinical presentation to the single most appropriate, guideline-concordant screening intervention that should be ordered or performed today.

Soldaki öğeye tıklayın, sonra eşleşen sağdaki öğeye tıklayın

Öğeler

A 42-year-old female with average disease risk. Her most recent cervical cytology with HPV co-testing was performed at age 40 and was negative. She has never undergone breast imaging.
A 67-year-old male with a 35-pack-year smoking history who successfully quit smoking 10 years ago. He underwent a normal screening colonoscopy at age 62 and has no other major medical conditions.
A 23-year-old female who is asymptomatic and reports being sexually active with a new partner. Her last cervical cytology was performed at age 21 and was normal.
A 66-year-old female with documented adequate prior negative cervical cancer screenings. She had a normal screening mammogram at age 65 and a normal colonoscopy at age 60. She has never undergone bone density testing.

Eşleşmeler

Cevabı ve açıklamayı göster

Cevap

The 42-year-old female matches with initiating biennial screening mammography. The 67-year-old male former smoker matches with ordering annual low-dose chest CT and a one-time abdominal aortic ultrasound. The 23-year-old sexually active female matches with chlamydia and gonorrhea screening. The 66-year-old female matches with ordering a DEXA scan.
Each patient represents a classic demographic for specific USPSTF Grade A or B recommendations. The 42-year-old needs breast cancer screening (starts at age 40). The 67-year-old male smoker needs lung and AAA screening (based on age and smoking history). The 23-year-old needs STI screening (indicated for sexually active women <25). The 66-year-old female needs osteoporosis screening (starts at age 65 for women).

Adım Adım Çözüm

1
Evaluate the 42-year-old female for age-appropriate screenings.
She is due for breast cancer screening.
Current USPSTF guidelines recommend starting biennial screening mammography at age 40 for average-risk women. Her cervical screening is up to date.
2
Evaluate the 67-year-old male former smoker for age and exposure-appropriate screenings.
He is due for both lung cancer and abdominal aortic aneurysm (AAA) screening.
He has a >20 pack-year history and quit <15 years ago, meeting LDCT criteria. He is a male aged 65-75 with a smoking history, meeting AAA ultrasound criteria.
3
Evaluate the 23-year-old sexually active female.
She is due for STI screening.
All sexually active women younger than 25 years require annual screening for chlamydia and gonorrhea. She is not yet due for her next Pap smear.
4
Evaluate the 66-year-old female with up-to-date cancer screenings.
She is due for osteoporosis screening.
Routine screening for osteoporosis with a DEXA scan is recommended for all women aged 65 years and older.

Anahtar Kavram

Age, biological sex, and risk factor-based application of USPSTF preventive screening guidelines.
Soru 1587Soru →

A 3838-year-old male nurse is evaluated during a routine follow-up visit. Six weeks ago, he was diagnosed with latent tuberculosis infection after routine occupational screening revealed a positive interferon-gamma release assay. A chest radiograph at that time was normal. He was started on a daily regimen of isoniazid and pyridoxine. Prior to initiating therapy, his baseline hepatic transaminase levels and bilirubin were within normal limits.

Today, he reports that he feels well, exercises three times a week, and has no fatigue, nausea, vomiting, or abdominal pain. He drinks one glass of wine occasionally but has not consumed any alcohol in the past two weeks. Physical examination shows an anicteric patient with a non-tender abdomen and no hepatomegaly.

Current laboratory studies are as follows:

Laboratory TestResultReference Range
Aspartate aminotransferase (AST)135135 U/L10−4010-40 U/L
Alanine aminotransferase (ALT)165165 U/L7−457-45 U/L
Alkaline phosphatase8888 U/L40−12040-120 U/L
Total bilirubin0.80.8 mg/dL0.1−1.20.1-1.2 mg/dL

Which of the following is the most appropriate next step in the management of this patient's condition?

Cevabı ve açıklamayı göster

Cevap: Continue the current regimen and repeat laboratory studies in 2 to 4 weeks

Cevap

Continue the current regimen and repeat laboratory studies in 2 to 4 weeks
The correct answer is to continue the current regimen and repeat laboratory studies in 22 to 44 weeks. Isoniazid (INH) frequently causes a mild, asymptomatic elevation in hepatic transaminases in up to 10%10\% to 20%20\% of patients. This phenomenon is often transient, and patients can safely continue therapy. According to clinical guidelines, INH should only be discontinued if transaminases rise to greater than 33 times the upper limit of normal (ULN) in the presence of symptoms (e.g., fatigue, nausea, vomiting, abdominal pain), or greater than 55 times the ULN in the absence of symptoms. This patient is completely asymptomatic, and his AST (135135 U/L) and ALT (165165 U/L) are between 33 and 44 times the ULN. Therefore, he does not meet the criteria for stopping the medication. The safest and most appropriate next step is to continue the current treatment and closely monitor his liver function tests to ensure they do not exceed the 55 times ULN threshold.

Adım Adım Çözüm

1
Analyze the patient's clinical presentation and laboratory results.
The patient is completely asymptomatic but has elevated AST (135135 U/L) and ALT (165165 U/L).
Identifying the presence or absence of symptoms is critical for applying drug toxicity guidelines.
2
Calculate the degree of transaminase elevation relative to the upper limit of normal (ULN).
AST is approximately 3.43.4 times the ULN (135/40135 / 40). ALT is approximately 3.73.7 times the ULN (165/45165 / 45).
Guidelines for isoniazid hepatotoxicity rely on exact multiples of the ULN to dictate management.
3
Apply the guideline criteria for isoniazid-induced hepatotoxicity.
Isoniazid must be discontinued if transaminases are >3> 3 times the ULN with symptoms, OR >5> 5 times the ULN without symptoms. Because this patient is asymptomatic and his levels are <5< 5 times the ULN, he does not meet criteria for stopping the drug.
Up to 20% of patients on isoniazid develop transient, asymptomatic transaminitis that resolves without discontinuing therapy.
4
Select the appropriate follow-up management.
The patient should continue the medication and have his liver function tests rechecked in 22 to 44 weeks.
Close monitoring ensures that if the transaminitis worsens to >5> 5 times the ULN, the medication can be stopped promptly before fulminant liver failure occurs.

Anahtar Kavram

Management of isoniazid-induced hepatotoxicity requires continuing therapy and monitoring if transaminases are less than 5 times the upper limit of normal in asymptomatic patients.
Tahmini Süre:1m 30s
Soru 1588Soru →

An asymptomatic 67-year-old woman visits her primary care physician to review her preventive health needs. Her past medical history includes hypertension, diet-controlled type 2 diabetes mellitus, and a total abdominal hysterectomy with bilateral salpingo-oophorectomy performed 12 years ago for cervical intraepithelial neoplasia grade 3 (CIN 3). She takes amlodipine daily.

She has a 54 pack-year smoking history but successfully quit 16 years ago. She consumes a glass of wine on weekends and denies any illicit drug use.

Her records indicate the following recent preventive evaluations:
- Screening colonoscopy at age 61 revealed no polyps.
- Screening mammography 6 months ago was interpreted as normal (BI-RADS 1).
- Dual-energy x-ray absorptiometry scan at age 65 showed a T-score of -1.4 at the lumbar spine and -1.2 at the femoral neck.
- Her most recent vaginal cuff cytology combined with human papillomavirus co-testing was performed 4 years ago and was negative.
- She received the 20-valent pneumococcal conjugate vaccine and a two-dose recombinant zoster vaccine series at age 65. She had her annual influenza vaccination 1 month ago.

Physical examination today is unremarkable. Her blood pressure is 128/78 mmHg, and her body mass index is 26 kg/m².

Which of the following is the most appropriate next step in this patient's preventive care?

Cevabı ve açıklamayı göster

Cevap: Vaginal cuff cytology and human papillomavirus testing

Cevap

Vaginal cuff cytology and human papillomavirus testing
The correct answer is vaginal cuff cytology and human papillomavirus testing. Under normal circumstances, cervical cancer screening is discontinued at age 65 with a history of adequate negative prior screening, or immediately following a total hysterectomy for benign indications. However, this patient underwent a hysterectomy for cervical intraepithelial neoplasia grade 3 (CIN 3). According to current ASCCP consensus guidelines, individuals treated for CIN 2, CIN 3, or adenocarcinoma in situ must undergo continued surveillance for 25 years post-treatment, even if this timeline extends beyond age 65. Acceptable surveillance includes HPV testing or co-testing every 3 years. Because her last co-test was 4 years ago, she is currently due for screening.

Adım Adım Çözüm

1
Evaluate the patient's gynecologic history and identify indications for continued screening.
The patient had a hysterectomy for CIN 3 twelve years ago. Standard guidelines require cessation of screening at age 65 or after a total hysterectomy for benign disease, but CIN 2/3 is a strict exception.
Prior high-grade dysplasia carries a long-term risk of vaginal cuff malignancy.
2
Determine the required duration and interval for post-CIN 3 screening.
Guidelines mandate continued screening for 25 years post-treatment. The recommended interval for co-testing is every 3 years. Since her last test was 4 years ago, she is currently overdue.
This establishes vaginal cuff evaluation as the definitively indicated next step.
3
Assess the patient's eligibility for lung cancer screening based on her smoking history.
She is 67, has >20 pack-years, but quit 16 years ago. The USPSTF cutoff for screening cessation is quitting >15 years ago.
This rules out the need for an annual low-dose CT scan.
4
Review the remaining preventive interventions (colonoscopy, bone density, AAA screening).
Colonoscopy is not due for another 4 years. Bone density scan is not due for at least another 1-3 years based on mild osteopenia. AAA screening is strictly for males.
Confirms that all other provided options are not indicated at today's visit.

Anahtar Kavram

Patients who have undergone a hysterectomy for cervical intraepithelial neoplasia grade 2 or 3 (CIN 2/3) must continue targeted screening of the vaginal cuff for 25 years post-treatment, superseding the usual age 65 cessation rule.
Soru 1589Soru →

A 4545-year-old man comes to the clinic for a routine follow-up visit. Four weeks ago, he was diagnosed with active pulmonary tuberculosis and started on a daily regimen of isoniazid, rifampin, pyrazinamide, and ethambutol, along with pyridoxine. He reports feeling much better, with resolution of his initial fever, night sweats, and cough. He specifically denies any abdominal pain, nausea, vomiting, dark urine, or unusual fatigue. He has no history of liver disease and does not consume alcohol. Vital signs are within normal limits. Physical examination shows no scleral icterus, and the abdomen is soft and non-tender with no hepatomegaly.

Laboratory studies show:
TestResultReference Range
Total bilirubin0.90.9 mg/dL0.10.1 - 1.21.2 mg/dL
Aspartate aminotransferase (AST)145145 U/L1010 - 4040 U/L
Alanine aminotransferase (ALT)160160 U/L1010 - 4040 U/L
Alkaline phosphatase9595 U/L4040 - 120120 U/L

Which of the following is the best next step in patient management?

Cevabı ve açıklamayı göster

Cevap: Continue the current medication regimen and recheck liver function tests in 1 to 2 weeks

Cevap

Continue the current medication regimen and recheck liver function tests in 1 to 2 weeks.
The correct approach is to continue the current medication regimen and monitor closely. Isoniazid, rifampin, and pyrazinamide are all known to be hepatotoxic. Mild, asymptomatic elevation of aminotransferases is a common, often transient adverse effect observed during the first few weeks of therapy (occurring in 10%10\% to 20%20\% of patients). Standard guidelines recommend discontinuing hepatotoxic tuberculosis medications only if the aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels exceed 33 times the upper limit of normal (ULN) in the presence of symptoms (e.g., nausea, vomiting, abdominal pain, jaundice), OR if they exceed 55 times the ULN in the absence of symptoms. In this vignette, the patient's AST (145145 U/L) and ALT (160160 U/L) are approximately 44 times the ULN. Because he is completely asymptomatic, the threshold to discontinue therapy has not been reached.

Adım Adım Çözüm

1
Evaluate the patient's symptoms related to potential hepatotoxicity.
The patient denies abdominal pain, nausea, vomiting, dark urine, or fatigue.
The presence or absence of symptoms determines the threshold for discontinuing hepatotoxic tuberculosis medications.
2
Analyze the laboratory results relative to the reference ranges.
AST is 145145 U/L (roughly 3.63.6 times the upper limit of normal) and ALT is 160160 U/L (44 times the upper limit of normal). Total bilirubin and alkaline phosphatase are normal.
Quantifying the degree of aminotransferase elevation is required to apply standard treatment guidelines.
3
Apply standard management guidelines for drug-induced liver injury in tuberculosis treatment.
Since the patient is asymptomatic and the transaminases are less than 55 times the upper limit of normal, the regimen should be continued with close monitoring.
Mild asymptomatic transaminitis occurs in up to 20% of patients on isoniazid and often resolves spontaneously without requiring treatment interruption.

Anahtar Kavram

Management of first-line tuberculosis medication hepatotoxicity requires discontinuing drugs if aminotransferases exceed 3 times the upper limit of normal in symptomatic patients, or 5 times the upper limit in asymptomatic patients.
Tahmini Süre:1m 15s
Soru 1590Soru →

A 35-year-old woman comes to the primary care clinic for a routine follow-up visit. Two months ago, she was diagnosed with an unprovoked deep vein thrombosis of the right lower extremity and was appropriately started on rivaroxaban. She has no other medical conditions and takes no other medications. During the interview, she appears visibly distressed and states, "I have been feeling very down and overwhelmed since my diagnosis, so I plan to start taking an over-the-counter St. John's wort supplement to improve my mood. Additionally, my aunt told me that because I am on a strong blood thinner, I need a screening head MRI to check for hidden bleeding, and she said I should start getting annual mammograms immediately to be safe." Which of the following is the most appropriate initial counseling response by the physician?

Cevabı ve açıklamayı göster

Cevap: It is understandable to feel overwhelmed, but St. John's wort can decrease the effectiveness of your blood thinner; furthermore, a screening head MRI and mammography are not indicated for you at this time.

Cevap

The most appropriate response empathetically validates the patient's emotional distress while correctly educating her on the drug-herbal interaction (St. John's wort decreases rivaroxaban efficacy) and accurately applying preventive and diagnostic guidelines (no indication for screening head MRI or mammography at age 35).
This response represents the best initial communication strategy because it first validates the patient's emotional distress, which builds rapport and trust. It then clearly and accurately educates the patient about a severe pharmacokinetic interaction: St. John's wort is a well-known, potent inducer of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp). Because rivaroxaban is cleared via these pathways, coadministration would significantly decrease its plasma concentration, putting the patient at high risk for a recurrent thromboembolism. Finally, the response correctly educates the patient that she does not meet the criteria for screening mammography (which typically begins at age 40 according to USPSTF guidelines) and that routine head imaging is never indicated to screen for bleeding in asymptomatic patients on anticoagulants.

Adım Adım Çözüm

1
Evaluate the physician's communication approach.
The physician must validate the patient's feelings of being overwhelmed rather than dismissing them or acting paternalistically.
Establishing empathy and a strong therapeutic alliance is essential before correcting patient misconceptions or refusing requested tests.
2
Assess the pharmacologic safety of St. John's wort in this patient.
Identify that St. John's wort is a potent inducer of CYP3A4 and P-glycoprotein.
Rivaroxaban is metabolized by CYP3A4 and is a P-gp substrate; induction of these pathways will lower its plasma concentration and significantly increase the risk of recurrent DVT.
3
Evaluate the need for the requested screening tests (head MRI and mammogram).
Determine that routine head MRIs are not indicated for asymptomatic patients on anticoagulation, and screening mammography is generally initiated at age 40 for average-risk women.
Performing unnecessary tests increases healthcare costs, patient anxiety, and the risk of false-positive cascades.

Anahtar Kavram

Effective patient counseling involves empathetic validation of concerns combined with accurate education regarding dangerous pharmacokinetic interactions (e.g., St. John's wort inducing CYP3A4/P-gp) and strict adherence to evidence-based preventive screening guidelines.
Soru 1591Soru →

A 58-year-old woman with a history of recurrent major depressive disorder and newly diagnosed nonvalvular atrial fibrillation presents to the clinic for a follow-up visit. She is currently taking citalopram. At her last visit, apixaban was prescribed for stroke prophylaxis. Today, she informs the physician, "I threw that prescription away. I don't want to take synthetic chemicals. I have decided to manage my heart condition naturally with St. John's wort and a daily aspirin instead." The patient is alert, oriented, and correctly states that not taking apixaban increases her risk of an ischemic stroke, but she says she accepts this risk. Which of the following is the most appropriate next step in management?

Cevabı ve açıklamayı göster

Cevap: Explore the patient's underlying fears regarding synthetic medications and clarify her understanding of her proposed regimen.

Cevap

The most appropriate next step is to explore the patient's underlying fears regarding synthetic medications and clarify her understanding of her proposed regimen.
The correct answer focuses on exploring the patient's fears and beliefs. In the context of patient counseling and health education, a patient's refusal of standard-of-care therapy should be met with curiosity rather than confrontation or immediate acceptance. By using open-ended questions to explore her specific aversion to 'synthetic chemicals' and her understanding of her alternative regimen, the physician builds trust. This therapeutic alliance is necessary before any effective health education regarding the inadequacy of aspirin for her condition, or the risks of her alternative plan, can be received by the patient.

Adım Adım Çözüm

1
Assess the patient's clinical decision-making capacity.
The patient clearly understands her diagnosis, the proposed treatment, and the risks of refusing treatment (stroke), indicating intact capacity.
Before proceeding with counseling or ethical interventions, the physician must establish that the patient is capable of making her own medical decisions.
2
Evaluate the patient's alternative treatment plan.
The patient wants to use St. John's wort and aspirin. This is medically insufficient for AFib stroke prophylaxis and poses a drug-interaction risk (serotonin syndrome) with her citalopram.
Understanding the flaws in the patient's self-directed care plan helps guide the educational focus of the conversation.
3
Determine the best communication strategy.
Employ active listening and open-ended questions to explore her aversion to 'synthetic chemicals'.
Directly challenging the patient, overriding her autonomy, or ignoring the issue damages the patient-physician relationship. Exploring her specific fears allows the physician to provide targeted, empathetic health education.

Anahtar Kavram

When a patient with decision-making capacity refuses recommended treatment, the most appropriate initial step is to use patient-centered counseling skills to explore their underlying beliefs, fears, and rationale without judgment.
Tahmini Süre:1m 30s
Soru 1592Soru →

A 58-year-old cisgender male presents to the clinic to establish care. He reports feeling well and has no acute symptoms. His past medical history is notable for HIV infection, diagnosed 10 years ago, and essential hypertension. He is currently maintained on a daily antiretroviral regimen of bictegravir, emtricitabine, and tenofovir alafenamide, with a most recent CD4 count of 520 cells/mm³ and an undetectable viral load. He has a 30-pack-year smoking history but successfully quit 5 years ago. His last preventive health visit was 3 years ago, during which he underwent a screening colonoscopy with normal findings. His vaccination records confirm receipt of a Tdap booster 3 years ago and an inactivated influenza vaccine 2 weeks ago. He has never received any pneumococcal or herpes zoster vaccines. Vital signs and physical examination today are unremarkable.

Which of the following preventive interventions are currently indicated for this patient? (Select all that apply)

Geçerli olan tümünü seçin

Cevabı ve açıklamayı göster

Cevap: Low-dose chest computed tomography; 20-valent pneumococcal conjugate vaccine (PCV20); Recombinant zoster vaccine

Cevap

The indicated preventive interventions for this patient are low-dose chest computed tomography (LDCT), the 20-valent pneumococcal conjugate vaccine (PCV20), and the recombinant zoster vaccine.
The correct selections represent three distinct guideline-concordant interventions for this patient. First, annual low-dose chest computed tomography is recommended by the USPSTF for adults aged 50 to 80 years with a minimum 20 pack-year smoking history who currently smoke or have quit within the past 15 years. This patient is 58, has a 30 pack-year history, and quit 5 years ago, perfectly meeting the criteria. Second, the Advisory Committee on Immunization Practices (ACIP) recommends that adults aged 19 to 64 years with specific underlying conditions (including HIV) who have not previously received a pneumococcal conjugate vaccine receive either a single dose of PCV20 or a dose of PCV15 followed by a dose of PPSV23. Thus, PCV20 is fully indicated. Finally, the recombinant zoster vaccine is recommended as a 2-dose series for all adults aged 50 and older, as well as for those 19 and older who are immunocompromised. Since this patient is both 58 and has HIV, he has dual indications for this vaccine.

Adım Adım Çözüm

1
Evaluate the patient's age and smoking history for cancer screening indications.
The patient is 58 years old, has a 30 pack-year history, and quit 5 years ago.
The USPSTF recommends annual LDCT for lung cancer screening in adults aged 50 to 80 with at least a 20 pack-year smoking history who currently smoke or quit within the past 15 years.
2
Assess immunization needs based on age and comorbid conditions (HIV).
The patient requires protection against pneumococcal disease and herpes zoster.
HIV is an immunocompromising condition that necessitates specific adult vaccinations, and his age (58) provides additional indications for certain vaccines.
3
Determine the correct pneumococcal vaccination sequence for a vaccine-naive adult with HIV.
The patient should receive either PCV20 alone or PCV15 followed by PPSV23.
ACIP guidelines dictate that higher-valent conjugate vaccines should be used as the primary dose for naive adults with high-risk conditions, making PPSV23 alone incorrect.
4
Evaluate indications for abdominal aortic aneurysm (AAA) screening.
AAA screening is not currently indicated.
Although the patient is a male with a history of smoking, the USPSTF age criteria for a one-time screening ultrasound is 65 to 75 years; this patient is 58.

Anahtar Kavram

Complex preventive care requires synthesizing age-based screening guidelines with disease-specific immunization protocols, particularly in patients with immunocompromising conditions like HIV.
Soru 1593Soru →

A 62-year-old woman is evaluated at home by a hospice physician for severe abdominal pain and vomiting. She has widely metastatic ovarian cancer complicated by extensive peritoneal carcinomatosis. Two weeks ago, she transitioned to home hospice care with the explicit goal of maximizing comfort. She strongly refuses any hospitalizations, surgical interventions, or invasive procedures, including nasogastric intubation.

For the past 48 hours, she has had worsening colicky abdominal pain, significant nausea, and multiple episodes of large-volume, bilious emesis. Her last bowel movement was four days ago. Her current medications include a continuous subcutaneous morphine infusion for baseline pain control.

Vital signs show a heart rate of 110/min and a blood pressure of 90/60 mmHg. Physical examination reveals a visibly distended abdomen that is tympanic to percussion. Bowel sounds are high-pitched and tinkling. The physician diagnoses a malignant mechanical bowel obstruction.

Which of the following is the most appropriate next step in the management of this patient?

Cevabı ve açıklamayı göster

Cevap: Administer subcutaneous octreotide

Cevap

Administer subcutaneous octreotide
Malignant bowel obstruction (MBO) is a common, distressing complication of advanced abdominal and pelvic malignancies, particularly ovarian cancer. In patients with terminal illness who refuse or are not candidates for surgical decompression or nasogastric (NG) tube placement, symptom management is the primary goal. Subcutaneous octreotide, a somatostatin analog, is highly effective for MBO in the hospice setting. It inhibits the secretion of gastric, pancreatic, and intestinal fluids and decreases splanchnic blood flow. This rapidly reduces intraluminal volume, thereby relieving bowel distension, colicky abdominal pain, nausea, and vomiting without the need for invasive mechanical decompression.

Adım Adım Çözüm

1
Identify the primary clinical diagnosis.
The patient is experiencing a malignant mechanical bowel obstruction (MBO) due to peritoneal carcinomatosis from ovarian cancer.
The symptoms of colicky pain, large-volume bilious emesis, lack of stool, and a distended, tympanic abdomen with high-pitched bowel sounds are classic for MBO.
2
Evaluate the patient's goals of care and constraints.
The patient is on home hospice care with strict comfort goals and a documented refusal of surgery, hospital transfer, or nasogastric (NG) tube placement.
Management must align with the patient's values, meaning symptom control must be achieved using non-invasive, home-based pharmacological therapies rather than mechanical decompression.
3
Select the appropriate targeted pharmacologic intervention.
Subcutaneous octreotide is selected to manage the MBO.
Because an NG tube is refused, GI secretions must be reduced pharmacologically. Octreotide inhibits GI secretions and reduces splanchnic blood flow, effectively alleviating the distension, colicky pain, and vomiting associated with MBO.

Anahtar Kavram

Pharmacologic management of malignant bowel obstruction in hospice care
Soru 1594Soru →

A 48-year-old man presents to the outpatient clinic to discuss the results of a recent excisional biopsy of a suspicious pigmented skin lesion. The pathology report confirms invasive malignant melanoma with positive margins. The physician prepares to deliver this diagnosis to the patient.

Arrange the following physician statements in the most appropriate chronological sequence for delivering this diagnosis, according to the standard consensus protocol for breaking bad news.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct sequence follows the SPIKES protocol: Setting up the interview, assessing Perception, obtaining an Invitation, giving Knowledge, and addressing Emotions.
The SPIKES protocol is a six-step framework for delivering bad news in clinical practice, designed to minimize patient distress and ensure clear communication. The chronological sequence begins with Setting up the interview (ensuring privacy and support), followed by assessing the patient's Perception (what they already know). The physician then obtains an Invitation (how much information they want) before giving the Knowledge (the diagnosis itself). Immediately following the disclosure, the physician must address Emotions with empathic responses before proceeding to Strategy and Summary (next steps).

Adım Adım Çözüm

1
Identify the communication framework being tested by the scenario.
The scenario requires the application of the SPIKES protocol for delivering bad news.
SPIKES is the gold-standard, evidence-based communication strategy for breaking bad news in medical practice.
2
Determine the initial preparatory and assessment statements.
The physician must first involve support systems (Setting) and then determine what the patient already suspects (Perception).
This establishes a safe environment and a baseline understanding before giving new facts.
3
Identify the transitional and informational statements.
The physician asks how much detail the patient wishes to receive (Invitation), followed by the direct delivery of the diagnosis with a warning shot (Knowledge).
This respects patient autonomy regarding information processing and delivers the facts clearly without premature reassurance.
4
Identify the immediate follow-up response.
The physician must respond to the patient's immediate reaction with empathy (Emotion) before moving to any treatment strategy.
Validating the patient's feelings is crucial to prevent overwhelming them with medical plans while they are in emotional shock.

Anahtar Kavram

The application of the SPIKES protocol for delivering bad news.
Soru 1595Soru →

A 6565-year-old man with symptomatic heart failure with reduced ejection fraction (LVEF 30%30\%) is evaluated in the clinic. He is currently taking lisinopril, metoprolol succinate, and spironolactone. His blood pressure is 118/75118/75 mmHg, and his heart rate is 6868/min. A basic metabolic panel shows a serum potassium of 4.64.6 mEq/L and a serum creatinine of 1.21.2 mg/dL. To further optimize his guideline-directed medical therapy, the physician decides to replace lisinopril with sacubitril-valsartan.

Which of the following are required steps in the execution and monitoring of this treatment transition? (Select all that apply)

Geçerli olan tümünü seçin

Cevabı ve açıklamayı göster

Cevap: Enforce a 3636-hour washout period after the final dose of lisinopril before administering the first dose of sacubitril-valsartan; Reassess serum potassium and renal function with a basic metabolic panel 11 to 22 weeks after initiating sacubitril-valsartan

Cevap

The required steps are enforcing a 36-hour washout period after the final lisinopril dose before starting sacubitril-valsartan, and reassessing serum potassium and renal function 1 to 2 weeks after initiation.
Sacubitril-valsartan is an angiotensin receptor-neprilysin inhibitor (ARNI) that improves morbidity and mortality in heart failure with reduced ejection fraction (HFrEF). Neprilysin normally degrades vasoactive peptides, including bradykinin. Because ACE inhibitors (like lisinopril) also inhibit bradykinin breakdown, the concurrent use of an ACE inhibitor and an ARNI significantly increases the risk of life-threatening angioedema. Therefore, a strict 3636-hour washout period is mandatory when transitioning from an ACE inhibitor to an ARNI. (Note: this washout is not required when transitioning from an ARB to an ARNI). Additionally, ARNIs can cause renal impairment and hyperkalemia. Because this patient is concurrently taking spironolactone (a potassium-sparing mineralocorticoid receptor antagonist), reassessing serum creatinine and potassium 11 to 22 weeks after initiation is a necessary monitoring step to prevent severe hyperkalemia or acute kidney injury.

Adım Adım Çözüm

1
Analyze the patient's current medication regimen and the planned transition.
The patient is transitioning from an angiotensin-converting enzyme (ACE) inhibitor (lisinopril) to an angiotensin receptor-neprilysin inhibitor (ARNI, sacubitril-valsartan).
Identifying the specific drug classes is essential for determining washout protocols and necessary monitoring.
2
Determine the washout requirements between an ACE inhibitor and an ARNI.
A strict 36-hour washout period is required.
Both ACE inhibitors and neprilysin inhibitors prevent the breakdown of bradykinin. Overlapping these medications drastically increases the risk of life-threatening angioedema.
3
Identify necessary laboratory monitoring based on the new regimen and concurrent medications.
A basic metabolic panel must be checked in 1 to 2 weeks.
ARNIs can decrease renal perfusion and increase potassium retention. This risk is compounded by the patient's concurrent use of spironolactone (a potassium-sparing diuretic).
4
Evaluate the distractors regarding biomarker monitoring and concurrent therapies.
BNP cannot be used for monitoring, and concurrent GDMT (spironolactone and metoprolol) must be continued.
Neprilysin degrades BNP, so sacubitril falsely elevates BNP levels (NT-proBNP should be used instead). Furthermore, stopping beta-blockers or MRAs inappropriately removes established mortality benefits.

Anahtar Kavram

Monitoring and transitioning protocols for Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) in Heart Failure
Tahmini Süre:2m 0s
Soru 1596Soru →

During a comprehensive health evaluation, a 38-year-old female patient inquires about her cancer risk. She currently feels well and has no physical complaints. Her medical history includes well-controlled asthma, for which she uses an albuterol inhaler as needed. She exercises regularly and follows a balanced diet.

Upon reviewing her family pedigree, the physician notes that her father was diagnosed with breast cancer at age 55, and her paternal grandmother died from ovarian cancer at age 62. Her mother and two younger sisters are alive and healthy. The patient has one child, whom she breastfed for 6 months. A thorough physical examination today, including a detailed clinical breast examination, reveals no palpable masses, skin changes, or axillary lymphadenopathy.

Based on current preventive care guidelines, which of the following is the most appropriate next step in management regarding this patient's cancer risk?

Cevabı ve açıklamayı göster

Cevap: Referral for formal genetic counseling and consideration of BRCA mutation testing

Cevap

The most appropriate next step is referral for formal genetic counseling and consideration of BRCA mutation testing.
This patient's family history includes male breast cancer and ovarian cancer, which are highly characteristic of a BRCA mutation (particularly BRCA2 for male breast cancer). According to the USPSTF guidelines, women with a family history associated with an increased risk for deleterious mutations in BRCA1 or BRCA2 genes should be referred for genetic counseling and, if indicated, genetic testing. It is a common misconception that paternal family history is less relevant for breast and ovarian cancer risk; however, these mutations are inherited in an autosomal dominant pattern and can be passed through the paternal line. Genetic counseling must precede the initiation of high-risk screening modalities or chemoprevention.

Adım Adım Çözüm

1
Analyze the patient's family history for high-risk hereditary cancer patterns.
The patient has a father with male breast cancer and a paternal grandmother with ovarian cancer.
Identifying hereditary cancer syndromes is crucial for implementing appropriate high-risk screening and prevention protocols.
2
Apply USPSTF guidelines for BRCA-related cancer risk assessment.
A family history of male breast cancer and ovarian cancer, even on the paternal side, strongly suggests a BRCA1 or BRCA2 mutation.
USPSTF recommends that primary care clinicians assess women with a family history suggestive of BRCA mutations and refer them for formal genetic counseling.
3
Evaluate the distractor options against standard test sequencing principles.
MRI, tamoxifen, and routine mammography at age 40 are inappropriate initial steps. TVUS and CA-125 are explicitly not recommended for ovarian cancer screening.
Proper test sequencing dictates that genetic risk must be formally established via counseling before initiating high-risk imaging or chemopreventive medications.

Anahtar Kavram

Women with a family history indicative of a potential BRCA mutation (including paternal history of breast/ovarian cancer or any male breast cancer) should be referred for formal genetic counseling before initiating high-risk screening or chemoprevention.
Soru 1597Soru →

Match each patient's clinical presentation with the most appropriate next step in preventive care according to current guidelines.

Soldaki öğeye tıklayın, sonra eşleşen sağdaki öğeye tıklayın

Öğeler

A 71-year-old man who reports a history of smoking 3 to 4 cigarettes daily for about three years in his early twenties, but has abstained since. He takes amlodipine for well-controlled hypertension.
A 35-year-old woman who feels well and has no breast masses. Her mother was diagnosed with breast cancer at age 46, and her maternal aunt had ovarian cancer at age 52.
A 69-year-old man with type 2 diabetes mellitus who received a single dose of the 15-valent pneumococcal conjugate vaccine (PCV15) exactly 12 months ago.
A 22-year-old man who has sex with men, reports inconsistent condom use with multiple recent partners, and had a negative fourth-generation HIV test last week.

Eşleşmeler

Cevabı ve açıklamayı göster

Cevap

The 71-year-old former light smoker matches with one-time abdominal aortic aneurysm screening; the 35-year-old woman with a strong family history matches with genetic counseling; the 69-year-old man who received PCV15 last year matches with PPSV23 administration; and the 22-year-old man with high-risk sexual behavior matches with HIV pre-exposure prophylaxis.
Each pairing directly applies current USPSTF and ACIP guidelines by correctly identifying the subtle triggers for screening or prophylaxis. The 71-year-old man meets the >100 lifetime cigarettes threshold for AAA screening. The 35-year-old woman's pedigree triggers BRCA risk assessment. The 69-year-old man completes his pneumococcal series with PPSV23 exactly one year after PCV15. The 22-year-old man's high-risk behavior combined with a negative HIV test warrants PrEP.

Adım Adım Çözüm

1
Evaluate the 71-year-old man's smoking history against vascular screening criteria.
He has smoked far more than 100 lifetime cigarettes, classifying him as an 'ever smoker'.
This qualifies him for the USPSTF Grade B recommendation for a one-time abdominal aortic aneurysm ultrasound screening for men aged 65-75, correcting the misconception that heavy pack-years are required for AAA screening.
2
Assess the 35-year-old woman's family oncology pedigree.
She has multiple relatives with BRCA-associated cancers (breast before age 50, ovarian cancer).
This triggers the USPSTF Grade B recommendation for administering a familial risk assessment tool and referring for genetic counseling.
3
Review the 69-year-old man's immunization timeline.
He received PCV15 exactly 12 months ago.
ACIP guidelines dictate that patients who receive PCV15 must be followed up with a dose of PPSV23 at least one year later.
4
Analyze the 22-year-old man's infectious disease risk profile.
He has high-risk sexual exposures and a recently confirmed negative HIV test.
He clearly meets criteria for initiating daily oral pre-exposure prophylaxis (PrEP).

Anahtar Kavram

Age- and risk-appropriate preventive care interventions require careful application of specific numeric thresholds (e.g., >100 lifetime cigarettes for AAA screening) and sequential timelines (e.g., PCV15 followed by PPSV23 at 1 year).
Tahmini Süre:1m 30s
Soru 1598Soru →

A 66-year-old man presents to the clinic for a follow-up visit. Three weeks ago, he was diagnosed with a left lower extremity unprovoked deep vein thrombosis. He was initially treated with low-molecular-weight heparin and subsequently transitioned to oral warfarin. Today, his international normalized ratio (INR) is subtherapeutic at 1.3. When asked about his medication adherence, the patient states, "I have been skipping doses because my leg feels perfectly fine, and I read online that blood thinners are basically rat poison. Instead, I am taking a high-dose ginseng extract and a vitamin K-rich multivitamin to dissolve the clot naturally." Furthermore, he insists on canceling his screening colonoscopy scheduled for next week, stating he refuses any procedure requiring sedation. His wife, who is present, is highly distressed and demands that the physician immediately declare him legally unfit to make medical decisions due to his dangerous nonadherence. Which of the following is the most appropriate next step in the management of this patient?

Cevabı ve açıklamayı göster

Cevap: Ask the patient to describe his understanding of the potential complications of an inadequately treated blood clot.

Cevap

The most appropriate next step is to explore the patient's understanding of the risks associated with an untreated deep vein thrombosis by asking him to describe the potential complications.
The correct answer is to ask the patient to describe his understanding of the potential complications of an inadequately treated blood clot. In a patient demonstrating severe nonadherence due to health misconceptions, the foundational step in health education and counseling is to explore the patient's illness perception and baseline knowledge. This approach, often part of the 'Ask-Tell-Ask' or 'Elicit-Provide-Elicit' framework, allows the physician to identify specific health literacy deficits before attempting to correct them. Furthermore, assessing the patient's understanding of the risks of refusing treatment is clinically required to determine his decision-making capacity. Premature reassurance, compromising with contraindicated therapies, or immediately deferring to legal authorities bypasses the essential physician-patient communication needed in this scenario.

Adım Adım Çözüm

1
Identify the multiple clinical and ethical challenges presented in the vignette.
The patient exhibits warfarin nonadherence, use of interacting supplements (ginseng and vitamin K), refusal of a colonoscopy, and the wife is demanding a declaration of incompetence.
Establishing all conflicting priorities is necessary to determine the safest and most effective initial intervention.
2
Evaluate the primary objective of health education in a nonadherent patient expressing significant health misconceptions.
The initial step must be to assess the patient's baseline knowledge, health literacy, and illness perception.
Using the 'Elicit-Provide-Elicit' framework prevents paternalistic lecturing and helps the physician determine if the patient actually understands the consequences of his actions.
3
Select the option that appropriately initiates this counseling framework while avoiding clinical and ethical pitfalls.
Asking the patient to describe his understanding of the complications addresses the core communication requirement.
It directly targets the root cause of the nonadherence without prematurely declaring incompetence, ignoring drug interactions, or misapplying preventive guidelines.

Anahtar Kavram

In patients exhibiting nonadherence due to health misconceptions, the initial step in patient counseling is to assess their baseline understanding and illness perception to guide targeted health education and evaluate decision-making capacity.
Tahmini Süre:1m 30s
Soru 1599Soru →

Match each clinical scenario with the most appropriate disposition and care setting.

Soldaki öğeye tıklayın, sonra eşleşen sağdaki öğeye tıklayın

Öğeler

75-year-old with community-acquired pneumonia, confusion, BUN 28 mg/dL, respiratory rate 32/min, and blood pressure 85/50 mmHg
82-year-old, post-operative day 5 for hip fracture repair, medically stable, requires maximum assistance for transfers, can tolerate only 45 minutes of physical therapy daily
62-year-old, post-stroke, medically stable with dense hemiparesis, capable of participating in 3 hours of intensive combined therapy daily
55-year-old with acute unprovoked deep vein thrombosis, normal vital signs, normal renal function, stable home environment

Eşleşmeler

Cevabı ve açıklamayı göster

Cevap

The pneumonia patient matches to ICU admission; the hip fracture patient matches to SNF transfer; the stroke patient matches to IRF transfer; and the DVT patient matches to home discharge.
Each patient's clinical stability and functional capacity directly dictates their required care setting: CURB-65 of 4 mandates ICU; ability to tolerate 3 hours of therapy qualifies for IRF; inability to tolerate intense therapy despite needing rehabilitation directs to SNF; and stable DVT is standardly managed as an outpatient.

Adım Adım Çözüm

1
Evaluate the clinical severity of acute medical conditions to determine the appropriate acuity level.
The pneumonia patient's CURB-65 score of 4 dictates ICU-level care. The DVT patient is hemodynamically stable with no high-risk features, allowing for safe outpatient management.
Risk stratification tools like CURB-65 guide the decision between critical care, standard inpatient admission, and outpatient management.
2
Assess the functional capacity and therapy tolerance for post-acute care transitions.
The stroke patient can tolerate 3 hours of daily therapy (IRF criteria), while the hip fracture patient can only tolerate 45 minutes (SNF criteria).
Regulatory and clinical criteria strictly differentiate post-acute care settings based on the intensity of rehabilitation the patient can actively participate in.

Anahtar Kavram

Appropriate disposition requires synthesizing objective clinical severity scores (e.g., CURB-65) with functional status, primarily a patient's ability to tolerate specific therapy durations.
Soru 1600Soru →

An occupational health clinic evaluates a prospective employee who is completing his onboarding physical. The patient is 4141 years of age and reports a history of mild intermittent asthma, for which he uses an albuterol inhaler occasionally. He weighs 105105 kg (231231 lbs) and is 178178 cm (55 ft 1010 in) tall, giving him a body mass index (BMI) of 3333 kg/m 2^2. He currently smokes 11 pack of cigarettes per day and has done so since age 1919. He states he has not undergone any medical evaluations or received any vaccinations since high school. Which of the following preventive health interventions are definitively indicated for this patient at today's visit? (Select all that apply)

Geçerli olan tümünü seçin

Cevabı ve açıklamayı göster

Cevap: Administration of the 20-valent pneumococcal conjugate vaccine (PCV20); Screening for type 2 diabetes mellitus with a fasting plasma glucose or hemoglobin A1c

Cevap

The indicated interventions are administration of the pneumococcal conjugate vaccine and screening for type 2 diabetes mellitus.
The correct interventions are based on combining the patient's risk factors with current guidelines. First, the patient is 41 years old and has a BMI of 33 kg/m^2 (obesity). The USPSTF recommends screening for type 2 diabetes in adults aged 35 to 70 years who are overweight or obese. Second, the patient has mild intermittent asthma and is a current smoker. The CDC's ACIP recommends pneumococcal vaccination (such as PCV20) for adults aged 19 to 64 years who have chronic medical conditions (including asthma) or who are cigarette smokers. Both of these interventions are strongly indicated at this visit.

Adım Adım Çözüm

1
Evaluate the patient's age and BMI for metabolic screening indications.
The patient is 41 years old with a BMI of 33 kg/m^2.
USPSTF guidelines recommend diabetes screening for overweight or obese adults starting at age 35.
2
Assess the patient's medical history and social history for immunization indications.
The patient has asthma and is a current smoker.
ACIP guidelines recommend pneumococcal vaccination for adults aged 19 to 64 years with asthma or a history of smoking.
3
Determine if the patient meets age cutoffs for lung, colon, or vascular screening based on his smoking history and age.
The patient is 41, which is below the threshold for LDCT (age 50), colon cancer screening (age 45), and AAA screening (age 65).
Applying age-specific parameters prevents unnecessary testing and resource overutilization.

Anahtar Kavram

Application of age- and risk-based preventive screening and immunization guidelines for adults.
ÖncekiSayfa 80 / 104Sonraki